Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely

Quest Diagnostics reported Q1 2026 revenue of $2.9 billion, up 9.2% year over year, and EPS of $2.24, up 15.5%, but shares slipped after earnings. The article frames DGX as a high-quality defensive business with strong market access, high barriers to entry, and steady but unspectacular growth. Forward valuation is about 19x earnings, suggesting the market is pricing in stable fundamentals rather than a reacceleration.

Analysis

Quest Diagnostics reported Q1 2026 revenue of $2.9 billion, up 9.2% year over year, and EPS of $2.24, up 15.5%, but shares slipped after earnings. The article frames DGX as a high-quality defensive business with strong market access, high barriers to entry, and steady but unspectacular growth. Forward valuation is about 19x earnings, suggesting the market is pricing in stable fundamentals rather than a reacceleration.